Skip to main content
Sandoz Group AG logo

Sandoz Group AG — Investor Relations & Filings

Ticker · SDZ ISIN · CH1243598427 LEI · 5493000JWK6XWFEUD320 SW Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2024-05-07 Earnings Release
Country CH Switzerland
Listing SW SDZ

About Sandoz Group AG

https://www.sandoz.com/

Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.

Recent filings

Filing Released Lang Actions
Sandoz reports first quarter 2024 sales
Earnings Release Classification · 100% confidence The document is explicitly titled 'MEDIA RELEASE' and begins by announcing 'net sales for the first quarter 2024' and providing key financial highlights (net sales, growth percentages, business segment performance). It includes CEO commentary, detailed tables for Q1 net sales by business and region, reiterates full-year guidance, and lists strategic milestones. This structure is characteristic of an Earnings Release (ER), which is the initial announcement of periodical financial results, focusing on key highlights rather than the comprehensive detail found in an Interim Report (IR) or Annual Report (10-K). The document is not a transcript (CT), a presentation (IP), or a simple announcement of a report publication (RPA). Q1 2024
2024-05-07 English
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
AGM Information Classification · 95% confidence The document is a press release dated April 30, 2024, announcing the results of the company's Annual General Meeting (AGM). It details the approval of all Board proposals, the re-election of directors, the approval of the dividend, and the endorsement of the Compensation Report. While it discusses AGM outcomes, the primary nature of the document is the announcement of these results, rather than the presentation materials (AGM-R) or the formal voting results document itself (DVA). Since it is an announcement summarizing key outcomes from a meeting where shareholder votes occurred, and it explicitly mentions the approval of the dividend and director compensation, it strongly relates to AGM activities. However, the core content is the summary of the meeting's outcomes, which fits best under AGM Information (AGM-R) as it summarizes the event and its key resolutions, or potentially DVA if the focus was purely on the vote tally. Given the context of summarizing the entire meeting's approved proposals, AGM-R is the most appropriate fit for the summary of the event itself, even though it is presented as a media release.
2024-04-30 English
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Regulatory Filings Classification · 95% confidence The document is titled 'Ad hoc announcement' and details a specific corporate event: the European Commission's marketing authorization for Pyzchiva®. It is a press release format, dated April 22, 2024, announcing a significant business development (product approval and commercialization rights). This type of announcement, which is not a full financial report (like 10-K or IR), nor a management change (MANG), nor a dividend notice (DIV), nor a formal regulatory filing like a proxy statement, best fits the category of a general regulatory announcement or press release that doesn't fit elsewhere. Since it is an 'Ad hoc announcement' regarding a business event, and it is not a formal financial report, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes. It is not an Earnings Release (ER) as it discusses a regulatory approval, not financial results.
2024-04-22 English
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
Earnings Release Classification · 99% confidence The document is explicitly titled "**MEDIA RELEASE**" and details a recent corporate event (opening a new production facility and investment figures) dated March 21, 2024. It contains forward-looking statements and boilerplate 'About Sandoz' information, typical of a press announcement intended for broad distribution to media and investors. This format strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) but rather an announcement of operational news and investment, it fits best as a general announcement. Given the options, 'ER' is often used for major periodic financial announcements, but this is more of a strategic operational update. However, since it is a formal announcement of significant business news, and not a specific regulatory form like DIRS or DIV, 'RNS' (Regulatory Filings / General Announcement) is the most appropriate fallback for a standard press release that doesn't fit the other specific categories like ER (which usually focuses on quarterly results figures). The document length (5405 chars) is substantial enough to be the release itself, not just a notification of a release. FY 2023
2024-03-21 English
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
Earnings Release Classification · 100% confidence The document text provides detailed financial results for the full year ended December 31, 2023, including net sales, gross profit, EBITDA, core EBITDA margin, cash flow, and debt structure. It explicitly states the period covered ('Full-year 2023') and presents comprehensive financial tables and management commentary on performance. This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of a 10-K, although this specific document is an 'Ad hoc announcement' and 'MEDIA RELEASE' detailing the results. Since it contains the full-year financial performance data, it is classified as the core Annual Report content. Furthermore, it mentions the upcoming Annual General Meeting (AGM) date (April 30, 2024) where the dividend proposal will be voted on, but the primary content is the full-year financial results, making 10-K the most appropriate classification for the financial data presented, rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). Given the comprehensive nature of the financial data covering the entire fiscal year, 10-K is the best fit among the provided options for a full-year financial disclosure. FY 2023
2024-03-13 English
Sandoz receives FDA approval for first and only denosumab biosimilars
Regulatory Filings Classification · 100% confidence The document is explicitly titled "MEDIA RELEASE" and announces the FDA approval of two biosimilar products (Wyost ® and Jubbonti ®) by Sandoz. It details the indications, safety information (Contraindications, Warnings, Adverse Reactions), and provides references to the full Prescribing Information. This format—a press release announcing a significant regulatory event (FDA approval) and providing key clinical/safety details—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is a specific announcement about a product approval rather than a comprehensive periodic financial report (like 10-K or IR), and it is not a transcript (CT) or a management discussion (MDA), the most fitting category is Earnings Release (ER) as these announcements often accompany or precede formal earnings reports, or Regulatory Filings (RNS) as a general announcement. Given the focus is on the FDA approval news itself, which is a major corporate event announcement, ER is a strong candidate, but since it's not explicitly tied to a quarterly/annual earnings period summary, RNS (Regulatory Filings - general regulatory announcements) is a safer fit for a standalone press release about a drug approval, unless it was clearly part of a quarterly earnings package. However, in many financial databases, major product/regulatory news releases are often categorized under ER if they drive market perception, or RNS if they are purely regulatory. Given the structure is a standard press release format announcing a major milestone, and it doesn't fit the other specific categories well (it's not a management change, dividend, or capital change), RNS is the most appropriate fallback for a significant, non-periodic regulatory announcement.
2024-03-05 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.